• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

眼镜蛇毒心脏毒素诱导洗涤过的大鼠血小板聚集:钙离子的双重作用。

Cobra venom cardiotoxin induces aggregation of washed rat platelets: dual effects of Ca2+.

作者信息

Huang S J, Kwan C Y

机构信息

Department of Physiology, Faculty of Medicine, University of Hong Kong, Pokfulam, Hong Kong.

出版信息

Res Commun Mol Pathol Pharmacol. 1996 Oct;94(1):103-10.

PMID:8948018
Abstract

The effects of cardiotoxin isolated and purified from the venom of Naja naja atra on the platelet aggregation were investigated using washed rat platelets prepared chromatographically. In the presence of 1 mM Ca2+, cardiotoxin concentration-dependently induced aggregation of platelets. While extracellular Ca2+ was necessary for the induction of aggregation by cardiotoxin, high concentration of Ca2+ (e.g., 5 mM) prevented cardiotoxin-induced aggregation. Cardiotoxin-induced platelet aggregation was also blocked by 1 mM Ni2+ but not by 100 microM indomethacin or 1 microM nifedipine, indicating that cardiotoxin-induced platelet aggregation involved Ca(2+)-entry pathway other than L-type Ca2+ channels. High concentration of Ca2+ may prevent cardiotoxin-induced aggregation by competing with cardiotoxin for binding site on the platelet membranes.

摘要

采用色谱法制备的洗涤大鼠血小板,研究了从眼镜蛇毒中分离纯化的心脏毒素对血小板聚集的影响。在存在1 mM Ca2+的情况下,心脏毒素浓度依赖性地诱导血小板聚集。虽然细胞外Ca2+对于心脏毒素诱导的聚集是必需的,但高浓度的Ca2+(例如5 mM)可阻止心脏毒素诱导的聚集。1 mM Ni2+也可阻断心脏毒素诱导的血小板聚集,但100 microM吲哚美辛或1 microM硝苯地平则不能,这表明心脏毒素诱导的血小板聚集涉及L型Ca2+通道以外的Ca(2+)内流途径。高浓度的Ca2+可能通过与心脏毒素竞争血小板膜上的结合位点来阻止心脏毒素诱导的聚集。

相似文献

1
Cobra venom cardiotoxin induces aggregation of washed rat platelets: dual effects of Ca2+.眼镜蛇毒心脏毒素诱导洗涤过的大鼠血小板聚集:钙离子的双重作用。
Res Commun Mol Pathol Pharmacol. 1996 Oct;94(1):103-10.
2
Cardiotoxin from Naja naja atra snake venom: a potentiator of platelet aggregation.眼镜蛇蛇毒中的心脏毒素:血小板聚集的增强剂。
Toxicon. 1984;22(3):463-70. doi: 10.1016/0041-0101(84)90090-4.
3
Cobra venom cardiotoxin induces perturbations of cytosolic calcium homeostasis and hypercontracture in adult rat ventricular myocytes.眼镜蛇毒心脏毒素可诱导成年大鼠心室肌细胞胞质钙稳态紊乱和超收缩。
J Mol Cell Cardiol. 1997 Oct;29(10):2759-70. doi: 10.1006/jmcc.1997.0511.
4
Effects of direct lytic factors from southern Chinese cobra venom on Ca2+ movement in rabbit aorta strip.中华眼镜蛇毒直接溶解因子对兔主动脉条Ca2+转运的影响。
Zhongguo Yao Li Xue Bao. 1993 Nov;14(6):500-4.
5
Effects of DK-002, a synthesized (6aS,cis)-9,10-Dimethoxy-7,11b-dihydro-indeno[2,1-c]chromene-3,6a-diol, on platelet activity.合成物(6aS,顺式)-9,10-二甲氧基-7,11b-二氢茚并[2,1-c]色烯-3,6a-二醇DK-002对血小板活性的影响。
Life Sci. 2006 Feb 2;78(10):1091-7. doi: 10.1016/j.lfs.2005.06.017. Epub 2005 Sep 8.
6
Activation of rabbit platelets by Ca2+ influx and thromboxane A2 release in an external Ca(2+)-dependent manner by zooxanthellatoxin-A, a novel polyol.一种新型多元醇——虫黄藻毒素 -A通过外部Ca(2+)依赖性方式使Ca2+内流并释放血栓素A2,从而激活兔血小板。
Br J Pharmacol. 1995 Jun;115(3):433-40. doi: 10.1111/j.1476-5381.1995.tb16352.x.
7
Inhibition of rat platelet aggregation by mycalolide-B, a novel inhibitor of actin polymerization with a different mechanism of action from cytochalasin-D.新型肌动蛋白聚合抑制剂Mycalolide-B对大鼠血小板聚集的抑制作用,其作用机制与细胞松弛素-D不同。
Thromb Haemost. 1998 Mar;79(3):614-9.
8
Tetrandrine differentially inhibits aggregation and ATP-release of rat platelets.汉防己甲素对大鼠血小板的聚集和ATP释放有不同程度的抑制作用。
Zhongguo Yao Li Xue Bao. 1996 Mar;17(2):105-8.
9
Effect of calcium on the vascular contraction induced by cobra venom cardiotoxin.钙对眼镜蛇毒心脏毒素诱导的血管收缩的影响。
Clin Exp Pharmacol Physiol. 2002 Sep;29(9):823-8. doi: 10.1046/j.1440-1681.2002.03723.x.
10
In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine.体外肾上腺素和胶原诱导的血小板钙动员及其被萘哌地尔、多沙唑嗪和硝苯地平抑制的情况。
Br J Clin Pharmacol. 1997 Apr;43(4):415-20. doi: 10.1046/j.1365-2125.1997.00560.x.